Cargando…

Germline EGFR mutations in lung cancer (Review)

Lung cancer is the leading cause of cancer-related death and familial lung cancer is a potential contributing factor. Epidermal growth factor receptor (EGFR) mutations are important events in carcinogenesis. The present study summarized the common germline mutations of EGFR, including T790M, V843I,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Minghui, Niu, Xiaoyu, Liu, Hongyu, Chen, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236141/ https://www.ncbi.nlm.nih.gov/pubmed/37274482 http://dx.doi.org/10.3892/ol.2023.13868

Ejemplares similares

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer
por: Burr, Risa, et al.
Publicado: (2023)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
por: Li, Xin, et al.
Publicado: (2020)

A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
por: Li, Dan, et al.
Publicado: (2023)

Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma
por: van der Leest, Cor, et al.
Publicado: (2018)

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
por: Mäkinen, Netta, et al.
Publicado: (2021)

Tumor metabolic reprogramming in lung cancer progression
por: Li, Xin, et al.
Publicado: (2022)

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
por: Lin, Xinqing, et al.
Publicado: (2021)

Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation
por: Ohtsuka, Kouki, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility
por: Liu, Mengyuan, et al.
Publicado: (2020)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Multiple mutations in the EGFR gene in lung cancer: a systematic review
por: Castañeda-González, Juan Pablo, et al.
Publicado: (2022)

EGFR Mutations and Lung Cancer
Publicado: (2005)

Germline VHL Mutation Discovered in Association with EGFR-Positive Lung Cancer and Metachronous Hepatocellular Carcinoma: A Case Report
por: Kuhlman, Justin J., et al.
Publicado: (2021)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
por: Gong, Hao, et al.
Publicado: (2020)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

EGFR-mutated lung cancer: a paradigm of molecular oncology
por: Zhang, Zhenfeng, et al.
Publicado: (2010)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer
por: Li, Na, et al.
Publicado: (2022)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

A Novel Technique to Detect EGFR Mutations in Lung Cancer
por: Liu, Yuanbin, et al.
Publicado: (2016)

Exosomes: a new perspective in EGFR-mutated lung cancer
por: Jouida, Amina, et al.
Publicado: (2021)

Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
por: Sagan, Olivia A., et al.
Publicado: (2023)

Clinical and genomic features of Chinese lung cancer patients with germline mutations
por: Peng, Wenying, et al.
Publicado: (2022)

Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte–Duclos disease
por: Colby, Samantha, et al.
Publicado: (2016)

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
por: Sebastian, Martin, et al.
Publicado: (2014)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas
por: Han, Xiaoyu, et al.
Publicado: (2020)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
por: Eltayeb, Kamal, et al.
Publicado: (2022)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
por: Li, Yufeng, et al.
Publicado: (2023)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
por: Reita, Damien, et al.
Publicado: (2021)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
por: Wang, Xiaochun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2qvum444m3c593ie0horc6cd7p